Your English writing platform
Discover LudwigExact(3)
At the time of defervescence up to 5% of cases may develop dengue hemorrhagic fever and/or dengue shock syndrome (DHF/DSS).
Dengue (DEN-2) patients usually recover fully within days (< 1% mortality), but some individuals, especially those with prior dengue exposure, may develop dengue hemorrhagic fever (DHF).
It is estimated that the disease is a potential threat to almost half of the world's population; some individuals, mostly children, may develop dengue hemorrhagic fever, a severe and often fatal form of the disease.
Similar(57)
While dengue infection often causes mild to high fever and lasts only a week or so, some patients develop dengue haemorrhagic fever, which is far more serious and kills about 22,000 people a year, many of them children.
It has been estimated that worldwide, about 100 million individuals annually develop dengue fever, including about 250,000 with hemorrhagic dengue fever [1].
Most of the more than 50 million people sickened by dengue virus each year develop dengue fever, a weeklong bout of joint and muscle pain.
Most persons infected with dengue viruses are asymptomatic or develop dengue fever (DF).
One out of four people may develop symptoms similar to dengue fever and consist of mild fever, a bumpy rash, headaches, joint pain and conjunctivitis, that can last between two and seven days.
In severe cases, the increased vascular permeability results in circulatory compromise and the patient may develop potentially life-threatening dengue shock syndrome (DSS).
This work supports the importance of dengue surveillance improvement and may help developing dengue-control programs.
Subacute thyroiditis may develop during the course of dengue fever and should be included as a manifestation of expanded dengue syndrome.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com